（二）会议召开地点：价值在线（www.ir-online.cn） （三）会议召开方式：网络互动方式 证券代码：003042 证券简称：中农联合 公告编号：2023-003 山东中农联合生物科技股份有限公司关于 举办 2022 年度暨 2023 年第一季度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 山东中农联合生物科技股份有限公司（以下简称"公司"）将于 2023 年 4 月 28 日在巨潮资讯网（www.cninfo.com.cn）披露《2022 年年度报告全文》《2022 年 年度报告摘要》及《2023 年第一季度报告》。为便于广大投资者更加全面深入地 了解公司经营业绩、发展战略等情况，公司定于 2023 年 5 月 8 日（星期一）15:00- 16:30 在"价值在线"（www.ir-online.cn）举办 2022 年度暨 2023 年第一季度网上 业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。具体情 况如下： 一、说明会召开的时间、地点和方式 （一）会议召开时间：2023 年 5 月 8 日（星期一）15 ...

证券代码：003042 证券简称：中农联合 编号：2022-001 山东中农联合生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------|---------------------------------------------------------------------------|---------------------------------------------------------| | | | | | | ☐ 特定对象调研 | ☐分析师会议 | | | ☐媒体采访 | 业绩说明会 | | 投资者关系活动类别 | ☐ 新闻发布会 | ☐ 路演活动 | | | ☐现场参观 | | | | ☐ | 其他（请文字说明其他活动内容） | | 形式 ☐ | 现场 网上 | ☐ 电话会议 | | 参与单位名称及人员姓名 | 线上参与公司 2021 者 | 年度暨 2022 年第一季度网上业绩说明会的投资 | | 时间 | 2022 年05月 10日 | 15:00-17:00 | | 地点 价值在线（ | | https:/ ...

证券代码：003042 证券简称：中农联合 公告编号：2022-063 山东中农联合生物科技股份有限公司 关于参加山东辖区上市公司 2022 年度 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强山东中农联合生物科技股份有限公司（以下简称"公司"）与 广大投资者之间的沟通交流，提升公司投资者关系管理水平，保护投资者权益， 公司将于 2022 年 11 月 16 日（星期三）14:00—16:00 参加由山东证监局、山东 上市公司协会联合举办，深圳市全景网络有限公司承办的"山东辖区上市公司 2022 年度投资者网上集体接待日活动"，现将有关事项公告如下： 本次投资者网上集体接待日活动将在深圳市全景网络有限公司提供的网上 平台采取网络远程方式举行，投资者可以登录全景·路演天下（http://rs.p5w.net） 参与本次活动。公司将与投资者通过网络在线交流形式，就公司治理及社会责任 /ESG、经营情况、发展战略、风险防控、投资者保护、三季度报告等投资者所关 心的问题，通过互动平台与投资者进行"一对多"形式的沟通，搭建上 ...

山东中农联合生物科技股份有限公司 2022 年第三季度报告 证券代码：003042 证券简称：中农联合 公告编号：2022-056 山东中农联合生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 山东中农联合生物科技股份有限公司 2022 年第三季度报告 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 495,071,251.71 | 34.08% ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[14]. - The net profit attributable to shareholders reached 80 million RMB, up 20% compared to the same period last year[14]. - The company's revenue for the reporting period was ¥1,011,491,766.78, representing a 24.71% increase compared to ¥811,054,448.27 in the same period last year[20]. - Net profit attributable to shareholders was ¥41,508,643.36, an increase of 85.51% from ¥22,375,391.45 year-on-year[20]. - The total profit for the period was ¥49,009,436.00, a 94.76% increase from ¥25,163,494.71, driven by higher operating revenue and improved gross margin[55]. - The company achieved scale production of key intermediates for neonicotinoid insecticides, ensuring a stable supply for its products[48]. - The company reported a significant increase in accounts receivable, totaling ¥445,457,614, which is 12.96% of total assets, reflecting a 5.99% increase from the previous year[62]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a year-over-year growth of 15%[118]. - The company reported a significant decline in stock price, with a continuous drop for 20 trading days below the latest audited net asset value per share[119]. User Growth and Market Expansion - User data indicates a growth in active users by 25%, reaching 1.5 million users by the end of June 2022[14]. - The company is focusing on expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[14]. - The company plans to continue expanding its market presence and investing in new product development to sustain growth[59]. - Market expansion plans include entering two new provinces, which are projected to increase market share by 5%[118]. Product Development and Innovation - The company plans to launch three new products in the second half of 2022, focusing on organic pesticides and biocontrol agents[14]. - Research and development expenses increased by 30%, totaling 50 million RMB, to support innovation and new technology development[14]. - The company is actively developing new products, including the registration of the pesticide compounds triflumuron and benzoylurea[34]. - The company has successfully developed and launched new pesticide products, including a novel compound for nematode control, enhancing its product portfolio[46]. - The company is investing 100 million RMB in research and development for new technologies aimed at enhancing product efficiency[118]. Financial Strategy and Investments - The company is exploring potential acquisitions to enhance its market position and expand its product portfolio[14]. - The company has committed to a project with an annual production capacity of 3,300 tons of pesticide raw materials, with a total investment of RMB 25,000,000.00, achieving 100% of the planned investment[78]. - The total investment amount for the reporting period was ¥220,158,085.17, representing a 48.97% increase compared to ¥150,059,326.36 in the same period last year[67]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[118]. Risk Management - The company has identified key risks including regulatory changes and market competition, with strategies in place to mitigate these risks[14]. - The company is actively pursuing market expansion and new product development in the agricultural biotechnology sector[69]. - The company has implemented measures to mitigate risks associated with foreign exchange fluctuations, including strict management of accounts receivable and purchasing credit insurance for export payments[73]. - The company is focused on risk analysis related to derivative investments, including market price fluctuations and customer default risks[73]. Environmental and Social Responsibility - The company emphasizes safety and environmental protection, achieving recognition as a "2022 Provincial Green Factory" for its subsidiary[36]. - The company is committed to green and low-carbon development, optimizing resource utilization and maximizing efficiency[36]. - The company has increased its environmental protection investments and aims to further enhance emission reduction and environmental governance levels[85]. - The company actively engages in social responsibility initiatives, including donations to local educational and agricultural development projects[106]. Shareholder and Governance Matters - No cash dividends will be distributed for the current fiscal year, as the company aims to reinvest profits into growth initiatives[4]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing[117]. - The company will handle any rights issues or stock splits according to the regulations of the Shenzhen Stock Exchange[117]. - The company has established a profit distribution policy to enhance transparency and protect the rights of public investors[121]. Compliance and Legal Matters - The company has not experienced significant changes in accounting policies or principles compared to the previous reporting period[73]. - The company has not encountered any significant changes in the feasibility of its projects or reasons for not meeting planned progress or expected benefits[78]. - The company has fulfilled all commitments related to share management as of the reporting period[117]. - The company will ensure that the board votes in favor of refunding investors if the IPO prospectus is found to have significant issues[122].

Financial Performance - The company's revenue for Q1 2022 was CNY 419,024,555.20, representing a 14.84% increase compared to CNY 364,865,914.40 in the same period last year[3] - Net profit attributable to shareholders was CNY 23,934,028.38, a 30.72% increase from CNY 18,309,536.86 year-over-year[3] - The total operating revenue for Q1 2022 was CNY 419,024,555.20, an increase of 14.8% compared to CNY 364,865,914.40 in the same period last year[17] - The total profit for Q1 2022 reached CNY 28,083,118.93, up from CNY 21,847,623.91 in the same period last year, reflecting a growth of 28.5%[19] - Operating profit for Q1 2022 was CNY 28,052,816.32, compared to CNY 21,962,155.08 in Q1 2021, indicating an increase of 27.5%[19] - The net profit for Q1 2022 was CNY 23,934,028.38, an increase of 30.5% compared to CNY 18,309,536.86 in Q1 2021[19] - The total comprehensive income for Q1 2022 was CNY 23,910,742.98, an increase from CNY 18,421,173.88 in Q1 2021[20] - The basic and diluted earnings per share remained stable at CNY 0.22 for both Q1 2022 and Q1 2021[20] Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 77,047,987.38, a decline of 129.95% compared to negative CNY 33,507,032.37 in the previous year[8] - The cash flow from operating activities showed a net outflow of CNY 77,047,987.38, worsening from a net outflow of CNY 33,507,032.37 in the previous year[23] - The company reported cash inflows from operating activities of CNY 250,461,187.75, compared to CNY 220,316,195.05 in the previous year[21] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 393,182,892.99, down from CNY 639,413,763.66 at the end of Q1 2021[24] - The company's cash and cash equivalents as of March 31, 2022, were CNY 629,669,893.05, compared to CNY 575,933,319.95 at the end of Q1 2021, indicating a growth of 9.3%[14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,309,002,177.43, up 2.75% from CNY 3,220,519,913.33 at the end of the previous year[3] - The total assets of the company as of March 31, 2022, were CNY 3,309,002,177.43, compared to CNY 3,220,519,913.33 at the same time last year, reflecting a growth of 2.8%[15] - The total liabilities increased to CNY 1,658,170,350.13 from CNY 1,593,652,077.90, which is an increase of 4.1%[15] Shareholder Information - The company had a total of 19,688 common shareholders at the end of the reporting period[10] Research and Development - Research and development expenses increased by 37.47% to CNY 16,600,512.51 from CNY 12,075,347.94 in the same period last year[8] - Research and development expenses for Q1 2022 were CNY 16,600,512.51, up from CNY 12,075,347.94, representing an increase of 37.1% year-over-year[17] Other Financial Metrics - The weighted average return on equity was 1.46%, slightly up from 1.44% in the previous year[3] - The company incurred a credit impairment loss of CNY -922,995.92 in Q1 2022, compared to CNY -68,494.03 in Q1 2021[19] - The company received government subsidies amounting to CNY 341,733.16, which was a decrease of 59.33% compared to the previous year[8] - The gross profit for Q1 2022 was CNY 28,510,407.65, reflecting a gross margin of approximately 6.8%[17] - The total operating costs for Q1 2022 amounted to CNY 390,514,147.55, up 14% from CNY 342,942,507.96 in Q1 2021[17] - Accounts receivable increased to CNY 295,353,946.87 from CNY 224,555,559.59, representing a rise of 31.5% year-over-year[14] - The company reported a significant increase in accounts receivable, which rose by 31.53% to CNY 295,353,946.87 from CNY 224,555,559.59[7] - Inventory levels rose to CNY 445,771,293.08, up from CNY 410,485,068.93, marking an increase of 8.6%[14] - Short-term borrowings increased by 98.74% to CNY 459,273,751.29, reflecting a higher demand for working capital[7] - The cash outflow from investing activities was CNY 77,905,467.91, significantly higher than CNY 21,974,442.25 in the previous year[23]

Financial Performance - The company's operating revenue for 2021 was ¥1,625,072,614.01, representing a 3.63% increase compared to ¥1,568,185,277.06 in 2020[19]. - The net profit attributable to shareholders for 2021 was ¥98,594,923.92, a decrease of 4.76% from ¥103,525,728.78 in 2020[19]. - The basic earnings per share for 2021 was ¥0.96, down 23.81% from ¥1.26 in 2020[19]. - The company's total revenue for 2021 was CNY 1,530,147,420.14, representing a year-on-year increase of 4.29%[63]. - The agricultural sector contributed ¥1,530,147,420.14, accounting for 94.16% of total revenue, with a growth of 4.29% year-on-year[60]. - The company achieved export revenue of CNY 471.76 million, accounting for 29.03% of total revenue[48]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 12%[131]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[199]. Dividend and Share Capital - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares (including tax) based on a total of 109,600,000 shares, with no bonus shares issued[4]. - A cash dividend of ¥2.00 per 10 shares (before tax) will be distributed, totaling ¥21,920,000.00, which accounts for 100% of the profit distribution[150][151]. - The company will also increase its share capital by 3 shares for every 10 shares held, resulting in a total capital increase of 32,880,000 shares, raising the total share capital to 142,480,000 shares[151]. Market and Industry Trends - The global pesticide market is projected to grow at a compound annual growth rate (CAGR) of 2.3% over the next five years, driven by population growth and increased food demand[30]. - The domestic pesticide market size is expected to reach ¥541 billion by 2025, with a CAGR of 3.6% from 2020[30]. - The pesticide industry is increasingly recognized for its role in ensuring effective supply of important agricultural products and promoting green development during the 14th Five-Year Plan period[32]. - The company reported a significant increase in the market concentration of the pesticide industry, with leading companies capturing a larger market share[29]. Research and Development - The company has established a complete pesticide production and R&D system, with 46 invention patents obtained by the end of the reporting period[34]. - The company has a strong focus on independent research and development, with several patented technologies enhancing production efficiency and reducing costs[43]. - The company has successfully developed proprietary pesticide products, including "Fluopyram" and "Trifloxystrobin," with patents granted in multiple countries[34]. - The company is investing 200 million RMB in R&D for new technologies in bio-agriculture over the next two years[131]. - Research and development expenses increased by 20% in 2021, totaling 100 million RMB, to support new technology initiatives[134]. Operational Efficiency - The company has maintained its main business operations without any changes since its listing[18]. - The company’s integrated production chain includes intermediates, active ingredients, and formulations, providing safe, environmentally friendly, and efficient pesticide products[34]. - The company has implemented a comprehensive salary management system that includes basic salary, position salary, and performance bonuses to attract and retain talent[147][148]. - The company has increased safety investment and enhanced safety measures, including the implementation of HAZOP analysis to identify safety hazards in production processes[183]. Environmental Commitment - The company has increased its environmental protection investment in recent years, ensuring that current emissions meet national standards, and will further promote emission reduction[101]. - The company has implemented measures to ensure compliance with environmental regulations and standards[165]. - The company was recognized as a "Water-Saving Enterprise" in Shandong Province, reflecting its commitment to resource recycling and efficiency[172]. - The company has adopted a clean production approach, using natural gas as fuel to minimize air pollution and environmental impact[172]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report, indicating potential operational risks in future developments[4]. - The company recognizes market competition risks and plans to address these through continuous innovation and improvement in production processes[100]. - The company faces risks from price fluctuations of its main products, which include pesticide raw materials and intermediates, due to market competition and environmental policies[102]. - The company is committed to risk mitigation during project implementation, ensuring timely completion and production contributions[103]. Corporate Governance - The company adheres to strict governance practices, ensuring compliance with relevant laws and regulations, and maintaining transparency in information disclosure[109]. - The company has established a well-defined corporate governance structure, including a board of directors and supervisory board, ensuring independent operation[112]. - The company has implemented a registration system for insider information to enhance transparency[139]. - The company has actively participated in governance and decision-making, ensuring the protection of minority shareholders' rights[142]. Strategic Initiatives - The company plans to enhance its market share by strengthening its marketing system and expanding both domestic and international markets in 2022[99]. - The company aims to complete the construction of several projects, including the bromopropyl raw material project and the formulation project, to optimize product layout and enhance profitability[99]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[131]. - The company is focused on maintaining a sustainable growth trajectory while navigating market challenges and opportunities[118].

证券代码：003042 证券简称：中农联合 公告编号：2021-040 山东中农联合生物科技股份有限公司 关于参加山东辖区上市公司 2021 年度 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步增强与广大投资者的互动交流，切实提高公司透明度、规范运作和 治理水平，山东中农联合生物科技股份有限公司（以下简称"公司"）将参加由 山东监管局、山东上市公司协会联合举办的"山东辖区上市公司 2021 年度投资 者网上集体接待日活动"，现将有关事项公告如下： 本次活动将通过深圳市全景网络有限公司提供的互联网平台举行，投资者可 登录"全景•路演天下"网站（http://rs.p5w.net）参与本次活动，互动交流时间为 2021 年 11 月 16 日（星期二）14:00-16:00。 届时公司董事会秘书颜世进先生及证券事务代表徐伟勋先生将通过网络在 线形式与投资者进行交流沟通，欢迎广大投资者积极参与。 特此公告。 山东中农联合生物科技股份有限公司 董事会 2021 年 11 月 13 日 ...

Financial Performance - The company's revenue for Q3 2021 reached ¥369,242,131.99, representing a 21.00% increase compared to the same period last year[2] - Net profit attributable to shareholders was ¥23,951,925.77, a significant increase of 402.19% year-on-year[2] - The basic earnings per share (EPS) for the period was ¥0.22, reflecting a 266.67% increase compared to the previous year[2] - The company's total revenue for Q3 2021 was 49,172,749.15, a decrease of 48.54% compared to the previous period due to a decline in product sales gross margin[7] - Net profit for Q3 2021 was 46,327,317.22, representing a 42.91% decrease from the previous year, primarily due to the decline in total profit[7] - The company's net profit for the third quarter of 2021 was CNY 46,327,317.22, down from CNY 81,144,297.59 in the same quarter of 2020, reflecting a decrease of approximately 42.8%[19] - The total comprehensive income for Q3 2021 was CNY 46,374,868.87, down from CNY 81,211,045.95 year-over-year[20] - Basic and diluted earnings per share for Q3 2021 were CNY 0.46, compared to CNY 0.99 in Q3 2020, reflecting a decline of 53.5%[20] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,009,318,933.62, marking a 30.81% increase from the end of the previous year[2] - The company's total liabilities as of September 30, 2021, were CNY 1,434,195,403.71, up from CNY 1,304,297,929.35 at the end of 2020, indicating an increase of about 9.93%[17] - Total assets reached CNY 3,009,318,933.62 as of September 30, 2021, compared to CNY 2,300,481,298.05 at the end of 2020, marking an increase of approximately 30.8%[17] - Total liabilities reached CNY 1,304,297,929.35, with current liabilities at CNY 1,132,371,147.38 and non-current liabilities at CNY 171,926,781.97[27] - Owner's equity totaled CNY 996,183,368.70, with retained earnings of CNY 536,111,965.95[28] Cash Flow - Cash flow from operating activities showed a negative net amount of ¥-86,760,326.50, indicating a decline of 148.90% year-to-date[2] - Operating cash inflow increased by 31.93% to 814,111,711.36, attributed to a higher cash collection ratio from sales[7] - Cash inflow from operating activities was CNY 814,111,711.36, an increase of 32% from CNY 617,074,366.44 in the previous year[22] - Cash outflow from operating activities totaled CNY 900,872,037.86, up from CNY 651,931,900.33, resulting in a net cash flow from operating activities of CNY -86,760,326.50[22] - Cash inflow from investment activities was CNY 410,070,260.00, significantly higher than CNY 24,859,288.00 in the previous year[23] - Cash outflow from investment activities reached CNY 801,484,500.46, compared to CNY 122,018,809.00 in the same period last year, leading to a net cash flow from investment activities of CNY -391,414,240.46[23] - Cash inflow from financing activities was CNY 1,049,698,181.25, a substantial increase from CNY 431,799,691.65 in the previous year[23] - The net increase in cash and cash equivalents for the period was CNY 47,046,943.78, compared to CNY 22,958,718.82 in the same period last year[23] - The ending balance of cash and cash equivalents was CNY 240,498,339.10, up from CNY 140,668,257.78 at the end of the previous year[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,395[9] - The largest shareholder, China Agricultural Production Materials Group, holds 30.57% of the shares, totaling 33,500,000 shares[10] - The shareholder voting rights delegation agreement signed on August 31, 2021, increased the voting rights held by China Agricultural Production Materials Group from 6.73% to 9.20%[12] - The company issued new shares, resulting in a 33.33% increase in share capital to 109,600,000.00[7] - Capital reserves increased by 152.17% to 841,742,975.63, driven by the premium from the initial public offering[7] Operational Highlights - The company has made progress on its project to produce 3,300 tons of pesticide raw materials, with trial production starting in July 2021[12] - The company is in the process of expanding its market presence and developing new products, as indicated by the ongoing construction of the bromopropyl project[12] - The company reported a decrease in research and development expenses to CNY 41,763,144.09 in Q3 2021 from CNY 47,165,463.43 in Q3 2020, a reduction of approximately 11.5%[19] Financial Adjustments - The adjustment for the new leasing standard resulted in a reduction of retained earnings by CNY 359,701.72[28] - The company recognized a right-of-use asset of CNY 3,324,022.46 and a corresponding lease liability of CNY 3,247,426.97 due to the new leasing standard[28] - The company reported a significant reduction in asset impairment losses by 80.86%, amounting to -1,848,304.40, due to rising product sales prices[7] - Financial expenses decreased by 41.36% to 14,000,590.41, due to reduced exchange losses and increased interest income[7] Audit Information - The company has not undergone an audit for the third-quarter report[29]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2021, representing a year-on-year increase of 15%[16]. - The company's operating revenue for the first half of 2021 was ¥811,054,448.27, a decrease of 6.17% compared to the same period last year[21]. - The net profit attributable to shareholders was ¥22,375,391.45, representing a significant decline of 70.70% year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥19,834,140.41, down 73.70% from the previous year[21]. - The total profit for the first half of 2021 was CNY 25,163,494.71, down from CNY 89,836,696.81 in the previous year, indicating a decrease of about 72%[162]. - The company's net profit margin for the first half of 2021 was approximately 2.83%, compared to 10.88% in the first half of 2020[160]. - The company reported a significant loss of 12,530,12 CNY in operating profit from its subsidiary engaged in chemical product production[71]. Revenue Breakdown - The revenue from the pesticide industry accounted for 91.86% of total revenue, amounting to ¥745,056,556.16, down 7.17% from ¥802,575,541.49[52]. - The company's revenue in the pesticide industry was approximately ¥745.06 million, representing a year-over-year decrease of 7.17%[54]. - Domestic sales decreased by 12.28% to ¥576,239,537.92, while international sales increased by 13.18% to ¥234,814,910.35[53]. Cost and Profitability - The gross profit margin improved to 35%, up from 30% in the same period last year, indicating better cost management and pricing strategies[16]. - The company's gross profit margin decreased significantly, leading to a total profit of ¥25,163,494.71, a decline of 71.99% from ¥89,836,696.81 in the previous year[50]. - The company's operating costs increased by 2.67% despite a decrease in revenue, primarily due to a significant rise in raw material prices[34]. Research and Development - Research and development expenses increased by 25% to 100 million RMB, focusing on innovative pesticide formulations and sustainable agricultural practices[16]. - The company applied for 5 domestic invention patents and 4 PCT patents in the first half of 2021, with significant international patent applications in 15 countries[36]. - Research and development expenses were reduced by 18.83% to ¥27,277,499.13 from ¥33,603,863.63[50]. Market Expansion and Strategy - The company plans to launch two new pesticide products in Q4 2021, aiming to capture a larger market share in the agricultural sector[16]. - The company is expanding its market presence in Southeast Asia, with plans to establish distribution channels in three new countries by the end of 2021[16]. - The company focuses on expanding both domestic and international markets, enhancing customer service, and developing new products to improve competitiveness[35]. Environmental and Safety Initiatives - The company emphasizes safety and environmental protection, with advanced waste treatment facilities and recognition as a key chemical enterprise by the Shandong provincial government[41]. - The company has implemented pollution prevention measures and invested in environmental protection facilities, ensuring that major pollutants meet discharge standards and are reduced effectively[86]. - The company has established an online monitoring system for wastewater discharge, with real-time data uploads and monthly third-party testing to ensure compliance with environmental standards[91]. Financial Health and Investments - The company achieved a net cash inflow from financing activities of ¥489,778,171.62, an increase of 345.49% compared to ¥109,941,080.32 in the previous year[50]. - The company reported a total asset value of ¥2.9 billion at the end of the reporting period, with cash and cash equivalents amounting to ¥413.18 million, representing 14.25% of total assets[60]. - The company invested approximately ¥150.06 million during the reporting period, a 166.66% increase compared to the previous year[63]. Legal and Compliance Matters - The company reported a total of 212.94 million yuan in a lawsuit against Jiangsu Huangma Agricultural Chemical Co., which has not been successfully executed, resulting in a provision for bad debts[105]. - There are no significant litigation or arbitration matters reported during the reporting period[108]. - The company has not faced any administrative penalties for environmental issues during the reporting period, indicating compliance with environmental laws and regulations[91]. Shareholder and Equity Information - The company raised a total of CNY 590.74 million by issuing 27.4 million shares at a price of CNY 21.56 per share during its IPO[136]. - The total number of shares increased from 82.2 million to 109.6 million after the issuance, resulting in a dilution of earnings per share[136]. - The company has a total of 38 million yuan in approved guarantees during the reporting period, with an actual guarantee amount of 11.9 million yuan, which accounts for 7.66% of the company's net assets[127].